Generate Biomedicines Inc.
GENB | NASDAQ
$14.46
-$1.31 (-8.31%)
At close: Oct 30, 2026, 4:00 PM ET
$14.45
-$0.01 (-0.07%)
Pre-market:
Nov 2, 2026, 7:37 AM ET
Fiscal Year Period Ending | FY 2025 Dec 31, 2025 | FY 2024 Dec 31, 2024 |
|---|---|---|
Revenue | 31.89M | 20.46M |
Cost of Revenue | n/a | n/a |
Gross Profit | 31.89M | 20.46M |
Operating Income | -235.07M | -196.94M |
Interest Income | 13.66M | 18.12M |
Pretax Income | -222.8M | -181.17M |
Net Income | -203.15M | -173.77M |
Selling & General & Admin | 42.26M | 42.09M |
Research & Development | 224.7M | 175.31M |
Other Expenses | n/a | n/a |
Operating Expenses | 266.96M | 217.4M |
Interest Expense | 1.14M | 2.12M |
Selling & Marketing Expenses | n/a | n/a |
Cost & Expenses | 266.96M | 217.4M |
Income Tax Expense | 163K | 212K |
Shares Outstanding (Basic) | 50.09M | 127.45M |
Shares Outstanding (Diluted) | 50.09M | 127.45M |
EPS (Basic) | -4.98 | -1.68 |
EPS (Diluted) | -4.98 | -1.68 |
EBITDA | -208.49M | -163.71M |
EBIT | -221.67M | -179.05M |
Depreciation & Amortization | 13.18M | 15.35M |
Add to Watchlist
Select watchlists to add or remove GENB